1 BioNT

Skip to main contentSkip to article

Skip to main contentSkip to article

Menu

Skip to main contentSkip to article

Access through your institution

Get Access

Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment

Volume 420, Issue 3, 11 January 1999, Pages 392-401

A technique of direct tension measurement of a strung fine wire

Author links open overlay panelKLangVVassilakopoulos

Show more

Share

Cite

https://doi.org/10.1016/S0168-9002(98)01184-XGet rights and content

Abstract

We present a new technique of direct measurement of wire tensions in wire chambers. A specially designed circuit plucks the wire using the Lorentz force and measures the frequency of damped transverse oscillations of the wire. The technique avoids the usual time-consuming necessity of tuning circuit parameter to a resonance. It allows a fast and convenient determination of tensions and is straightforward to implement.

Introduction

Many techniques of measuring wire tensions in wire chambers are extensively covered in the literature 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16. Here, we are presenting a new scheme of performing this task inspired by the principle of generating sound by vibrating strings in an electric guitar. In our novel circuit the plucking is accomplished by forcing a voltage pulse through a wire placed in a static magnetic field. A plucked wire strung in a chamber undergoes damped transverse oscillations with frequencies given by the formula:f=n2LTρ,where f is the frequency of oscillations, L is the wire length, ρ is the linear density of the wire, T is the tension force stretching the wire, and n is the order of the harmonic. Frequency of these transverse oscillations can be directly measured by analyzing a waveform of the induced Faraday current.

The main difference between the method presented here and all other techniques known to us is that our circuit offers direct measurement of vibrational frequency (up to a calibration factor) without a usual necessity of tuning the instrument to the resonant frequency of a wire. Once a wire is placed in a magnetic field and is connected to the circuit, the period of oscillations – thus the tension – is determined automatically. This new technique allows the tension measurements to be performed significantly faster than using other methods. We have conducted many tests validating this technique using wires with lengths ranging from 5 to 100 cm. Our measurements were done in various conditions and show an excellent agreement between the expected and measured oscillation frequencies. In the following sections, we first briefly review the basic principles of the most commonly used setups for measuring wire tensions, and then describe in detail our technique and performed tests.

Figures

A conceptual diagram of the circuit for direct measurements of wire tensions.

A block diagram of the designed circuit to directly measure wire tensions.

A detailed schematics of the designed circuit to directly measure wire tensions.

An oscilloscope trace showing the shape of the wire plucking excitation pulse.

The oscilloscope trace of the induced signal from the oscillating wire. The signal is not exactly damped sinusoidal due to short range of the magnetic field.

The oscilloscope trace of the signal from the Cycle Gate Generator. The gate is spanning exactly 8 periods (5th through the 12th) is measured to detect the number of zero-crossings.

Show all figures

Section snippets

A brief general overview

The development of various wire chambers since early 1970s and the task of manufacturing reliable long-lived high-quality instruments motivated many different approaches to measuring tensions of wires. Over the years several types of methods have been developed differing in employed physics principles. They range from the most obvious and commonly used electromagnetic and electrostatic techniques to optical measurements. In this section we give a brief overview of various methods.

A

Circuit concept

The circuit which we designed is conceptually very simple, as illustrated in Fig. 1. It consists of an impulse current source, followed by a signal amplifier and a frequency detector. An optional acoustic amplifier was added to further facilitate the measurements. The principles behind the circuit are the Lorentz force to excite the wire mechanically and the Faraday law to induce a signal on the wire vibrating in a magnetic field. We have primarily tested it using a straw tube wire chamber, but 

Initial circuit implementation

The translation of this simple idea into a practical device required following all the basic low-noise circuit practices including a solid single point ground and careful shielding. In the initial trials we used a square voltage excitation pulse. The frequency of oscillations behaved erratically as a function of the tension of the wire. The source of this problem was found to be the interference of two out-of-phase oscillations induced on the wire. One was caused by the leading edge of the

Detailed circuit description

The circuit, shown in block diagrams in Fig. 2, can be divided into several main functional blocks: Free Running Pulse Generator, Pulse Shaper, Controlled Voltage Source, Analog Switch, Difference Amplifier, Clipping Amplifier, Low Pass Filter, Zero Crossing Detector, Binary Counter, Cycle Gate Generator, NAND gate, Decade Counter, LCD, Free Running Crystal Clock, and Scope Synch. Below we discuss the functions of each part and refer to the detailed circuit schematics shown in Fig. 3.

The Free

Test results

To determine the functioning of the circuit many measurements were conducted with a variety of circuit parameters and wire conditions. In most tests we used a gold-plated tungsten wire with a 20 μm diameter and a measured linear density of ρ=61 μg/cm [18]. For our tests the wire was secured at different tensions by soldering it to two vertically spaced fixed points. The wire was first soldered at the top fixed point, then a weight was attached to it and after the wire stabilized it was soldered

Summary

We have designed and tested a new circuit to measure tensions of wires in wire chambers. Our simple technique of plucking the wire electromagnetically and analyzing the frequency of the induced signal is fast, robust and easy to implement. It offers a direct method of determining the tensions without a time-consuming necessity to tune the circuit to a resonance. Our tests showed better than 1% agreement between the applied and measured tension values. This work was supported in part by the U.S. 

References (18)

S. Graessle

Nucl. Instr. and Meth. A

(1995)

I. D'Antone

Nucl. Instr. and Meth. A

(1992)

N.J. Shenhav

Nucl. Instr. and Meth. A

(1993)

R.T. Jones

Nucl. Instr. and Meth. A

(1988)

D. Carlsmith

Nucl. Instr. and Meth. A

(1995)

K.B. Burns

Nucl. Instr. and Meth. A

(1973)

T. Regan

Nucl. Instr. and Meth. A

(1984)

Y. Hoshi

Nucl. Instr. and Meth. A

(1985)

M. Coupland

Nucl. Instr. and Meth. A

(1983)

There are more references available in the full text version of this article.

Cited by (5)

A novel electrical method to measure wire tensions for time projection chambers

2019, Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment

Citation Excerpt :

With the increasing size of these detectors, ranging from a few hundred tons for the short-baseline neutrino (SBN) experiments [2] to 10 kt for a single DUNE module [3], the numbers of wires can go from tens of thousands to hundreds of thousands.Different electromagnetic-based techniques of measuring wire tensions in wire chambers have been described in the literature [8–12].Here, we present a novel method using an electric-based system which resolves most of the difficulties of the laser-based setup.

Show abstract

A straw drift chamber spectrometer for studies of rare kaon decays

2004, Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment

Citation Excerpt :

Our decision to use CF4–C2H6 (50 : 50) was based on our own studies and those performed by Heinson and Rowe and other analysis .

Show abstract

Rapid measurement of tension in multi-wire arrays using free damped oscillations

2019, arXiv

A novel electrical method to measure wire tensions for time projection chambers

2018, arXiv

Development of a portable and fast wire tension measurement system for MWPC construction

2016, Chinese Physics C

Recommended articles (6)

Research article

Natural rubber (NR) biosynthesis: perspectives from polymer chemistry

Chemistry, Manufacture and Applications of Natural Rubber, 2014, pp. 30-67

Show abstract

Research article

Origin and money matter: The airline service quality expectations of international students

Journal of Hospitality and Tourism Management, Volume 31, 2017, pp. 244-252

Show abstract

Research article

An evaluation of science process skills of the science teaching majors

Procedia - Social and Behavioral Sciences, Volume 9, 2010, pp. 1592-1596

Show abstract

Research article

Evaluation of the toxicity of the essential oils of some common Chinese spices against Liposcelis bostrychophila

Food Control, Volume 26, Issue 2, 2012, pp. 486-490

Show abstract

Research article

Self-organizing production systems: Implications for product design

Procedia CIRP, Volume 79, 2019, pp. 546-550

Show abstract

Research article

Improving the mechanical properties of rubber floor tiles by rock powder particle as filler in natural rubber

Materials Today: Proceedings, Volume 5, Issue 7, Part 1, 2018, pp. 14907-14911

Show abstract

View full text

Copyright © 1999 Elsevier Science B.V. All rights reserved.

About ScienceDirect

Remote access

Shopping cart

Advertise

Contact and support

Terms and conditions

Privacy policy

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.

Visit journal homepage

Submit your paper

Open access options

Track your paper

Order journal

View articles

Free sample

Abstracting

Editorial board

Browse journals

Vacunas

Guide for authors

Guide for Authors

 Download Guide for Authors in PDF

Aims and scope

INTRODUCTION

• Types of article

• Contact details for submission

• Language

• Submission checklist

BEFORE YOU BEGIN

• Ethics in publishing

• Studies in humans and animals

• Declaration of interest

• Submission declaration and verification

• Use of inclusive language

• Authorship

• Changes to authorship

• Clinical trial results

• Copyright

• Role of the funding source

• Open access

• Informed consent and patient details

• Submission

PREPARATION

• Peer review

• Double anonymized review

• Article structure

• Essential title page information

• Highlights

• Structured abstract

• Keywords

• Artwork

• Tables

• References

• Video

• Supplementary material

AFTER ACCEPTANCE

• Proofs

• Offprints

AUTHOR INQUIRIES

Vacunas is a peer-reviewed journal supported by an advisory board of experts in the field of vaccinology. The aim of the journal is to contribute to the dissemination of the scientific advances made in the area of basic and applied research in the field of vaccine-preventable diseases in humans. It places special emphasis on aspects associated with planning and evaluation (epidemiology of vaccine-preventable diseases, development of vaccination programs, evaluation of the efficacy, effectiveness and efficiency of vaccinations). Vacunas publishes, in Spanish or in English, Editorials, Original Articles, Special Articles, Reviews, Strategies and Vaccination Programs. There are also sections on Literature Reviews, News and on Congresses associated with vaccinations. The peer review process is done anonymously by reviewers with expertise in the area of knowledge of each manuscript as well as experts in methodology or statistics, as determined by the Editorial board, which works towards maintaining an efficient editorial process in order for the manuscripts to be published as soon as possible.

Types of article

Originals: Research works on the immunogenicity, efficacy, effectiveness and safety of vaccines are accepted, as well as those on the microbiology, epidemiology, diagnosis, treatment, and prevention of immuno-preventable diseases. The recommended designs are analytical type in the form of clinical trials, community trials, cohort studies, case control studies, and seroprevalence studies. The maximum length of the text will be 3,000 words and up to a maximum of 8 Figures and/or Tables will be accepted. The number of literature references must not exceed 30. The article should have the following headings: Introduction, Material and methods, Results, Discussion and Conclusions, and will be accompanied by an abstract in Spanish and English of a maximum of 250 words structured in the following sections: Objective, Material and methods, Results and Conclusions.

Short Originals:

 This section will admit research works, which due to their special characteristics (including, but not limited to, a reduced number of observations, works with very specific aims and results, descriptive epidemiological studies, may be published in a shorter and more rapid form. The maximum length of the text will be 1,500 words, with 15 literature references and four Tables or Figures. They should be structured as an Original article and will also include a structured Abstract of approximately 250 words, in Spanish and in English. There must be no more than six authors.

Letters to the Editor:

This section will publish discussions and comments associated with publications in the Journal during the three previous months, as well as observations or experiences that could be summarized in a short text. The maximum length will be 600 words, with a maximum of 10 literature references and two Figures or Tables. There must be no more than four authors.

Other sections:

The Journal includes other sections, such as Editorials, Reviews. Special Articles, vaccination strategies, Questions and Answers, Literature Reviews, News, Conferences and Scientific Meetings, where the articles are commissioned by the Editorial Board. The authors who wish to contribute to any of these sections without having been commissioned should contact the Editor-in-Chief of the Journal. Works on vaccinations and immunopreventable diseases that are promoted by bodies of the Health Administration, University bodies or Scientific Societies will be particularly welcome.

Contact details for submission

You can send your manuscript at:​https://www.editorialmanager.com/vacun/

Language

This journal is published in Spanish and in English language.

Submission checklist

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

• E-mail address

• Full postal address

All necessary files have been uploaded:

Manuscript:

• Include keywords

• All figures (include relevant captions)

• All tables (including titles, description, footnotes)

• Ensure all figure and table citations in the text match the files provided

• Indicate clearly if color should be used for any figures in print

Graphical Abstracts / Highlights files (where applicable)

Supplemental files (where applicable)

Further considerations

• Manuscript has been 'spell checked' and 'grammar checked'

• All references mentioned in the Reference List are cited in the text, and vice versa

• Permission has been obtained for use of copyrighted material from other sources (including the Internet)

• A competing interests statement is provided, even if the authors have no competing interests to declare

• Journal policies detailed in this guide have been reviewed

• Referee suggestions and contact details provided, based on journal requirements

For further information, visit our Support Center.

Ethics in publishing

Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.

Studies in humans and animals

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

Declaration of interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

Authorship

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

Changes to authorship

Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Clinical trial results

In line with the position of the International Committee of Medical Journal Editors, the journal will not consider results posted in the same clinical trials registry in which primary registration resides to be prior publication if the results posted are presented in the form of a brief structured (less than 500 words) abstract or table. However, divulging results in other circumstances (e.g., investors' meetings) is discouraged and may jeopardise consideration of the manuscript. Authors should fully disclose all posting in registries of results of the same or closely related work.

Reporting clinical trials

Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram are available online.

Registration of clinical trials

Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with International Committee of Medical Journal Editors recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Elsevier supports responsible sharing

Find out how you can share your research published in Elsevier journals.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Open access

Please visit our Open Access page for more information.

Elsevier Researcher Academy

Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.

Informed consent and patient details

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article

Please submit your article via: https://www.editorialmanager.com/vacun/

Referees

Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our Support site. Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

Peer review

This journal operates a double anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

Double anonymized review

This journal uses double anonymized review, which means the identities of the authors are concealed from the reviewers, and vice versa. More information is available on our website. To facilitate this, please include the following separately:

Title page (with author details): This should include the title, authors' names, affiliations, acknowledgements and any Declaration of Interest statement, and a complete address for the corresponding author including an e-mail address.

Blinded manuscript (no author details): The main body of the paper (including the references, figures, tables and any acknowledgements) should not include any identifying information, such as the authors' names or affiliations.

Use of word processing software

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure

Subdivision - unnumbered sections

Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.

Introduction

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods

Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Results

Results should be clear and concise.

Discussion

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Appendices

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information

• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

• Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.

• Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Highlights

Highlights are optional yet highly encouraged for this journal, as they increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: example Highlights.

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

Structured abstract

A structured abstract, by means of appropriate headings, should provide the context or background for the research and should state its purpose, basic procedures (selection of study subjects or laboratory animals, observational and analytical methods), main findings (giving specific effect sizes and their statistical significance, if possible), and principal conclusions. It should emphasize new and important aspects of the study or observations.

The headings will consist of: «Objectives», «Materials and Methods», «Results» y «Conclusions».

Graphical abstract

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.

Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images and in accordance with all technical requirements.

Keywords

Immediately after the abstract, provide a maximum of 6 keywords, using British spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abbreviations

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Formatting of funding sources

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

Artwork

Image manipulation

Whilst it is accepted that authors sometimes need to manipulate images for clarity, manipulation for purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly. For graphical images, this journal is applying the following policy: no specific feature within an image may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or color balance are acceptable if and as long as they do not obscure or eliminate any information present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed in the figure legend.

Electronic artwork

General points

• Make sure you use uniform lettering and sizing of your original artwork.

• Embed the used fonts if the application provides that option.

• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.

• Number the illustrations according to their sequence in the text.

• Use a logical naming convention for your artwork files.

• Provide captions to illustrations separately.

• Size the illustrations close to the desired dimensions of the published version.

• Submit each illustration as a separate file.

• Ensure that color images are accessible to all, including those with impaired color vision.

A detailed guide on electronic artwork is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:

• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;

• Supply files that are too low in resolution;

• Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites). Further information on the preparation of electronic artwork.

Illustration services

Elsevier's Author Services offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

Figure captions

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References

Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.

Web references

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

References in a special issue

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

Reference style

Text: Indicate references by superscript numbers in the text. The actual authors can be referred to, but the reference number(s) must always be given.

List: Number the references in the list in the order in which they appear in the text.

Examples:

Reference to a journal publication:

1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun 2010;163:51–9. https://doi.org/10.1016/j.Sc.2010.00372.

Reference to a journal publication with an article number:

2. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. Heliyon. 2018;19:e00205. https://doi.org/j.heliyon.2018.e00205.

Reference to a book:

3. Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 2000.

Reference to a chapter in an edited book:

4. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, editors. Introduction to the electronic age, New York: E-Publishing Inc; 2009, p. 281–304.

Reference to a website:

5. Cancer Research UK. Cancer statistics reports for the UK, http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/; 2003 [accessed 13 March 2003].

Reference to a dataset:

[dataset] 6. Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. https://doi.org/10.17632/xwj98nb39r.1.

Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;​277​:927–34)(see also Samples of Formatted References).

Journal abbreviations source

Journal names should be abbreviated according to the List of Title Word Abbreviations.

Video

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Supplementary material

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

Proofs

One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or a link will be provided in the e-mail so that authors can download the files themselves. To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download the free Adobe Reader, version 9 (or higher). Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site.

If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and scan the pages and return via e-mail. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints

The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Author Services. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also check the status of your submitted article or find out when your accepted article will be published.

Solutions

Researchers

About Elsevier

How can we help?

Select location/language

Global - English

Copyright © 2021 Elsevier, except certain content provided by third parties

Cookies are used by this site. Cookie Settings

Terms and Conditions Privacy Policy Cookie Notice Sitemap

We use cookies to analyse and improve our service, to improve and personalise content, advertising and your digital experience. We also share information about your use of our site with our social media, advertising and analytics partners. Cookie Policy

Cookie SettingsAccept all cookies

Search SearchView Cart 0View accountView accountSign outSign inView accountSign outAbout usElsevier ConnectCareersR & D SolutionsClinical SolutionsResearch PlatformsResearch IntelligenceEducationAll SolutionsAuthorsEditorsReviewersLibrariansBooks and JournalsAuthor Webshop ↗

Access through your institution

Get Access

Vacunas

Volume 21, Issue 1, January–June 2020, Pages 69-72

Preguntas y respuestas

Vacunas contra el coronavirusCoronavirus vaccines

Author links open overlay panelL.UrbiztondoaG.Miradac

Show more

Share

Cite

https://doi.org/10.1016/j.vacun.2020.04.002Get rights and content

Section snippets

Cada día aparecen noticias que anuncian la aparición casi inminente de vacunas que solucionarán la pandemia por SARS-CoV-2. ¿Cuándo se podrá disponer de vacunas?

Es difícil aventurar cuándo se podrá disponer de vacunas contra la infección por coronavirus SARS-CoV-2. La aparición de la COVID-19 ha hecho pensar en las vacunas como la mejor manera de poder prevenirla, como ocurre habitualmente cuando aparece una nueva enfermedad infecciosa. En los medios de comunicación generalistas aparecen continuamente noticias que prevén que habrá vacunas en pocos meses; sin embargo, en la prensa científica los artículos sobre este tema son relativamente escasos.

¿Se pueden coordinar esfuerzos para conseguir avanzar con más rapidez en la obtención de vacunas contra la COVID-19?

La Coalition for Epidemic Preparedness Innovations (CEPI), una alianza fundada en Davos en 2017 por los gobiernos de Noruega e India, la Fundación Bill y Melinda Gates, el Wellcome Trust y el Foro Económico Mundial con la misión de acelerar el desarrollo de vacunas contra enfermedades infecciosas emergentes y permitir el acceso equitativo a estas vacunas para las personas durante los brotes, está trabajando con las autoridades sanitarias mundiales y los fabricantes de vacunas para apoyar el

¿Qué tecnologías se están utilizando en la investigación de las vacunas contra la COVID-19?

La CEPI está estudiando desde el mes de febrero el panorama de candidatos a la vacuna COVID-19 mediante el uso de todo tipo de fuentes que incluyen los productos candidatos a vacunas en evaluación de la lista autorizada y continuamente actualizada por la OMS, pero además la información procedente de convocatorias, comunicaciones directas con desarrolladores de vacunas, bases de datos de ensayos clínicos y financiadores, comunicados de prensa y literatura disponible públicamente.

A fecha de 8 de

El tiempo que se necesita habitualmente para hacer una vacuna es muy largo, de más de 5 o 10 años. ¿Se pueden acortar los plazos?

La necesidad de desarrollar rápidamente una vacuna contra el SARS-CoV-2 llega en un momento en que los conocimientos básicos de genómica y de biología estructural pueden hacer posible una nueva era en el desarrollo de vacunas. En la última década se ha pedido a la comunidad científica y a la industria de las vacunas que respondan urgentemente a las epidemias de gripe H1N1, Ébola, Zika y ahora SARS-CoV-2. Aunque la vacuna monovalente contra la gripe H1N1 no estuvo disponible antes de que la

¿Es seguro acortar los plazos?

Si tomamos como ejemplo la primera vacuna que ha iniciado la investigación clínica, se puede afirmar, a partir de la experiencia con vacunas para oncología, que la plataforma basada en ARNm es segura en humanos, pero no que esta vacuna COVID-19 lo sea. El National Institute of Allergy and Infectious Diseases (NIAID), que colabora con Moderna en el desarrollo de la vacuna, argumenta que el riesgo de retrasar el avance de las vacunas es mucho mayor que el riesgo de causar enfermedades en

¿Cómo es posible que en tan poco tiempo ya se disponga de prototipos de vacuna contra el SARS-CoV-2?

La gripe nos ha aportado experiencia científica en la posibilidad de aparición de pandemias gripales imprevistas en el tiempo. Por ello los laboratorios desarrolladores de vacunas han trabajado intensamente y en diferentes líneas de producción de vacunas con el fin de anticiparse a estas posibles situaciones. Lo mismo ha sucedido con otros virus potencialmente pandémicos. Los laboratorios han estado trabajando intensamente con moléculas candidatas a vacunas contra estos virus. Además, la

¿Qué se está investigando en España?

El Centro Nacional de Biotecnología (CNB) del Consejo Superior de Investigaciones Científicas (CSIC) tiene en marcha dos proyectos. Sonia Zúñiga, del equipo de Luis Enjuanes e Isabel Sola, está desarrollando una vacuna de virus completos. Esta vacuna podría proporcionar una respuesta más amplia que la de las vacuas de subunidades. Otro equipo del CSIC, que lidera el científico Mariano Esteban, trabaja en una vacuna de subunidades y quiere crear vectores virales modificados de Vaccinia que

First page preview

Open this preview in PDF

References (0)

Cited by (0)

Recommended articles (6)

Research article

Sarampión. Reemergencia en el camino de la erradicación

Vacunas, Volume 21, Issue 1, 2020, pp. 41-49

Show abstract

Research article

Factores relacionados con la decisión de los padres de no vacunar a sus hijos

Vacunas, Volume 21, Issue 1, 2020, pp. 4-10

Show abstract

Research article

Vacunación antigripal universal: perspectivas de futuro

Vacunas, Volume 20, Issue 2, 2019, pp. 72-81

Show abstract

Research article

Quo vadis en vacunas: desde la aproximación empírica a la nueva oleada tecnológica

Revista Española de Geriatría y Gerontología, Volume 55, Issue 3, 2020, pp. 160-168

Show abstract

Research article

Collateral effects of Covid-19 pandemic emergency response on worldwide immunizations

Vacunas, Volume 21, Issue 2, 2020, pp. 73-75

Research article

Vacunación en prematuros. Recomendaciones oficiales en España

Vacunas, Volume 21, Issue 1, 2020, pp. 1-3

View full text

© 2020 Elsevier España, S.L.U. All rights reserved.

About ScienceDirect

Remote access

Shopping cart

Advertise

Contact and support

Terms and conditions

Privacy policy

Access through your institution

Get Access

Vacunas

Volume 21, Issue 2, July–December 2020, Pages 121-128

Revisión

A review on Promising vaccine development progress for COVID-19 diseaseRevisión sobre el avance prometedor del desarrollo de vacunas frente a la enfermedad por COVID-19

Author links open overlay panelTafere MulawBelete

Show more

Share

Cite

https://doi.org/10.1016/j.vacun.2020.05.002Get rights and content

Abstract

The emergence of the strain of coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) that causes corona virus disease 2019 (COVID-19) and its impact on in the world have made imperative progress to develop an effective and safe vaccine. Despite several measures undertaken, the spread of this virus is ongoing. So far, more than 1,560,000 cases and 1000,000 deaths occurred in the world. Efforts have been made to develop vaccines against human coronavirus (CoV) infections such as MERS and SARS. However, currently, no approved vaccine exists for these coronavirus strains.

Such Previous research efforts to develop a coronavirus vaccine in the years following the 2003 pandemic have opened the door for the scientist to design a new vaccine for the COVID-19. Both SARS-CoV and SARS-CoV-2 has a high degree of genetic similarity and bind to the same host cell ACE2 receptor.

By using different vaccine development platforms including whole virus vaccines, recombinant protein subunit vaccines, and nucleic acid vaccines several candidates displayed efficacy in vitro studies but few progressed to clinical trials. This review provides a brief introduction of the general features of SARS-CoV-2 and discusses the current progress of ongoing advances in designing vaccine development efforts to counter COVID-19.

Resumen

La aparición de la cepa de coronavirus SARS-CoV-2 (síndrome respiratorio agudo severo por coronavirus 2), que causa la enfermedad por coronavirus 2019 (COVID-19), y su impacto a nivel mundial, ha urgido el avance hacia el desarrollo de una vacuna efectiva y segura. A pesar de las diversas medidas adoptadas, la diseminación de este virus es continua. Hasta la fecha, se han producido más de 1.560.000 casos y 1.000.000 de muertes en todo el mundo. Se han realizado esfuerzos para desarrollar vacunas frente a las infecciones por coronavirus humano (CoV), tales como MERS y SARS. Sin embargo, actualmente no existe ninguna vacuna autorizada para estas cepas de coronavirus.

Los esfuerzos previos sobre investigación, para desarrollar una vacuna frente a coronavirus en los años posteriores a la pandemia de 2003, han abierto la puerta a los científicos para diseñar una nueva vacuna para el COVID-19. Tanto SARS-CoV como SARS-CoV-2 poseen un alto grado de similitud genética y capacidad de adherirse al mismo receptor ACE2 de la célula huésped.

Utilizando diferentes plataformas para el desarrollo de vacunas, incluyendo vacunas de virus completos, vacunas de subunidades de proteína recombinante y vacunas de ácido nucleico, algunas de estas han mostrado su eficacia en estudios in vitro, pero pocas de ellas han progresado hacia ensayos clínicos. Esta revisión aporta una breve introducción a las características generales del SARS-CoV-2, y trata el progreso actual de los avances en curso para diseñar el desarrollo de vacunas frente al COVID-19.

Figures

Coronavirus structure.

Section snippets

Background

Viruses have a great potential to become a dangerous life-threatening and cause irreparable loss to human beings. Hardly the world learns to cope with one strain of virus when another emerges and poses a threat to the future of humanity. A similar situation has emerged when a new strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has not been previously known in human history. Coronaviruses (CoVs) are nonsegmented, enveloped, single-strand, positive-sense, ribonucleic

Current Sars-Cov-2 Vaccines Platforms

Effective SARS-CoV-2 vaccines are crucial for controlling the CoVs pandemic. Vaccines decrease disease severity, viral shedding, and person to person transmission. Currently, no vaccine has been licensed to prevent SARS-CoV-2 infection.14 There are different vaccine development platforms against SARS-CoV-2, including live attenuated virus, viral vectors, inactivated virus, subunit vaccines, recombinant DNA, and protein vaccines. Several studies are in progress, but requires months to years to

Inactivated Whole-Virus Vaccine

Inactivated whole-virus comprises the entire disease-causing virion which is inactivated physically (heat) or chemically. It has several antigenic parts to the host and can induce diverse immunologic responses against the pathogen. Inactivated whole-virus has several advantages, including low production cost, safe, and does not involve genetic manipulation. IWV is conventional vaccines with mature technology and may become the first SARS-CoV-2 vaccine put into clinical use.19 There are three

Viral Vector-Based Vaccine

Viral vector vaccine works by carrying a DNA express or antigen(s) into host cells, thereby eliciting cell-mediated immunity in addition to the humoral immune responses. Viral Vectors Vaccines characterized by strong immunogenicity and safety.33 Several viral vectors are available for vaccine development including vaccinia, modified vaccinia virus Ankara (MVA), adenovirus (Ad), adeno-associated virus (AAV), retrovirus/lentivirus, alphavirus, herpes virus, Newcastle disease virus, poxvirus, and

Virus-Like Particles Based Vaccine

Virus-like particles (VLPs) are"hollow-core" virus particles formed by the viral structural component with self-assembly character into nanostructure. VLP mimic the structure of the whole virus. VLPs can elicit innate immunity response via pathogen recognition receptors. VLPs represent advanced subunit vaccine with increased immunogenicity because they contain the structural protein of the virus. VLPs have a noninfectious and non-replicative property due to lose of genomic component. VLPs help

The most promising vaccines

The COVID-19 outbreak is rapidly increasing in the number of cases, deaths, and countries affected. Pharmaceutical companies are searching to develop an effective vaccine for controlling the COVID-19. Currently, several countries and Research institutions are developing vaccine against SARS-CoV-2. However, vaccine development could not be done overnight. After vaccine design and preparation, it will undergo safety and efficacy evaluation before entering clinical trials. Generally, three phases

Abbreviations

Ad5, Ad serotype 5, AAV, adeno-associated virus, ACE2; angiotensin-converting enzyme 2, CoVs; Coronaviruses, ChAdOx1; Chimpanzee adenovirus, DVs; DNA vaccines, MVA, modified vaccinia virus Ankara, SARS-CoV-2; severe acute respiratory syndrome coronavirus 2, WHO; World Health Organization, S protein;Spike Protein, RBD; receptor binding domain, VLPs;Virus-like particles, NDV; Newcastle disease virus

Funding

No funded

Conflict of interests

The authors declare no conflict of interests.

Acknowledgments

I would like to acknowledge the School of Pharmacy (University of Gondar) for providing the resources.

References (45)

N. Kushnir et al.

Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development

Vaccine.

(2012)

W. Gao et al.

Effects of a SARS-associated coronavirus vaccine in monkeys

Lancet.

(2003)

M.A. Shereen et al.

COVID-19 infection: origin, transmission, and characteristics of human coronaviruses

Journal of Advanced Research.

(2020)

J. Lan et al.

Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge

EBioMedicine.

(2015)

P.D. Minor

Live attenuated vaccines: historical successes and current challenges

Virology.

(2015)

B. Vellingiri et al.

COVID-19: A promising cure for the global panic

Sci Total Environ.

(2020)

I.M. Ibrahim et al.

COVID-19 spike-host cell receptor GRP78 binding site prediction

J Infect.

(2020)

H. Li et al.

SARS-CoV-2 and viral sepsis: observations and hypotheses

Lancet.

(2020)

C.C. Lai et al.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Int J Antimicrob Agents.

(2020)

F.A. Rabi et al.

SARS-CoV-2 and coronavirus disease 2019: what we know so far

Pathogens.

(2020)

View more references

Cited by (2)

Immunotherapeutic approaches to curtail COVID-19

2020, International Immunopharmacology

Show abstract

Recent Updates on COVID-19 Vaccine Platforms and Its Immunological Aspects: A Review

2020, Systematic Reviews in Pharmacy

Recommended articles (6)

Research article

Fiebre y vacunación infantil

Vacunas, Volume 21, Issue 2, 2020, pp. 105-110

Show abstract

Research article

Confidence toward vaccination as reported by parents of children admitted to a tertiary care hospital in Riyadh, Saudi Arabia: A cross sectional study

Vacunas, Volume 21, Issue 2, 2020, pp. 95-104

Show abstract

Research article

Influence of HLA-G polymorphism in antibody response to hepatitis B vaccination during the first year of life

Vacunas, Volume 21, Issue 2, 2020, pp. 76-81

Show abstract

Research article

Estado actual de las vacunas frente a la infección congénita por citomegalovirus: la paradoja de la inmunidad previa

Vacunas, Volume 21, Issue 2, 2020, pp. 111-120

Show abstract

Research article

Percepción de los errores en la vacunación en Cataluña: un estudio transversal

Vacunas, Volume 21, Issue 2, 2020, pp. 90-94

Show abstract

Research article

Purificación de la proteína L1 del virus del papiloma humano tipo 16 a partir E. coli SHuffle® T7

Vacunas, Volume 21, Issue 2, 2020, pp. 82-89

Show abstract

View full text

© 2020 Published by Elsevier España, S.L.U.

About ScienceDirect

Remote access

Shopping cart

Advertise

Contact and support

Terms and conditions

Privacy policy

avataravatar